Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies?

Affiliations

¹ Department of Nuclear Medicine, Lausanne University Hospital, Lausanne; Department of Nuclear Medicine, Geneva University Hospitals, Geneva. Electronic address: franz.buchegger@chuv.ch.
² Department of Biochemistry, University of Lausanne, Lausanne, Switzerland.
³ Department of Medical Oncology, University of Washington Medical Center, Seattle, USA.
⁴ Faculty of Medicine, University of Lausanne, Lausanne, Switzerland.
⁵ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA.
⁶ Department of Nuclear Medicine, Lausanne University Hospital, Lausanne.
⁷ Clinic Bois-Cerf, Onco-Hematology, Lausanne, Switzerland.

Comment

F Buchegger et al. Ann Oncol. 2013 Jul.

. 2013 Jul;24(7):1948-1949.

doi: 10.1093/annonc/mdt198. Epub 2013 May 23.

¹ Department of Nuclear Medicine, Lausanne University Hospital, Lausanne; Department of Nuclear Medicine, Geneva University Hospitals, Geneva. Electronic address: franz.buchegger@chuv.ch.
² Department of Biochemistry, University of Lausanne, Lausanne, Switzerland.
³ Department of Medical Oncology, University of Washington Medical Center, Seattle, USA.
⁴ Faculty of Medicine, University of Lausanne, Lausanne, Switzerland.
⁵ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA.
⁶ Department of Nuclear Medicine, Lausanne University Hospital, Lausanne.
⁷ Clinic Bois-Cerf, Onco-Hematology, Lausanne, Switzerland.

No abstract available

Comment on

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).
Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P, McNamara C, Caligaris-Cappio F, Stilgenbauer S, Marcus R, Trneny M, Dreger P, Montserrat E, Dreyling M; Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma. Ghielmini M, et al. Ann Oncol. 2013 Mar;24(3):561-76. doi: 10.1093/annonc/mds517. Epub 2012 Nov 21. Ann Oncol. 2013. PMID: 23175624 Free PMC article.

1. Ghielmini M, Vitolo U, Kimby E, et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) Ann Oncol. 2013;24:561–576. doi: 10.1093/annonc/mds517. - DOI - PMC - PubMed
1. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441–449. doi: 10.1056/NEJMoa041511. - DOI - PubMed
1. Goff L, Summers K, Iqbal S, et al. Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 ibritumomab tiuxetan as consolidation of first remission in patients with follicular lymphoma. J Clin Oncol. 2009;27:6094–6100. doi: 10.1200/JCO.2009.22.6258. - DOI - PubMed
1. Buchegger F, Antonescu C, Helg C, et al. 6 of 12 relapsed refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission. J Nucl Med. 2011;52:896–890. doi: 10.2967/jnumed.111.087460. - DOI - PubMed
1. Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010;28:4480–4484. doi: 10.1200/JCO.2010.28.4786. - DOI - PubMed